Evaluation of immunotherapy in the treatment of melanoma.
These data show that the extraordinary potency of the immune system can be harnessed to control or destroy melanoma. The proven impact has been limited for patients who have melanoma, but has been dramatic and lasting in selected groups. Recent improvements in understanding of immunology, including mechanisms regulating immune responses and methods of tumor cell escape, are already yielding improved clinical outcomes and potential avenues for extending benefits to more patients. Thus, although the full potential of this treatment modality has yet to be realized, the vanguard of the "treatment of tomorrow" has clearly arrived.
Faries
Mark B
MB
John Wayne Cancer Institute, 2200 Santa Monica Boulevard, Santa Monica, CA 90404, USA. fariesm@jwci.org
D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D016207:Cytokines / Q000187:drug effects; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D007370:Interferon Type I / Q000627:therapeutic use; D008545:Melanoma / Q000276:immunology / Q000628:therapy*; D011379:Prognosis; D015375:Receptors, Interleukin-2 / Q000627:therapeutic use; D011994:Recombinant Proteins; D012878:Skin Neoplasms / Q000276:immunology / Q000628:therapy*
D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D016207:Cytokines; D007370:Interferon Type I; D015375:Receptors, Interleukin-2; D011994:Recombinant Proteins